Search

Your search keyword '"Borrelli, C."' showing total 215 results

Search Constraints

Start Over You searched for: Author "Borrelli, C." Remove constraint Author: "Borrelli, C."
215 results on '"Borrelli, C."'

Search Results

1. Data report: X-ray fluorescence scanning of sediment cores, IODP Expedition 390/393 Site U1558, South Atlantic Transect

2. Data report: X-ray fluorescence scanning of sediment cores, IODP Expedition 390/393 Site U1557, South Atlantic Transect

3. Data report: X-ray fluorescence scanning of sediment cores, IODP Expedition 390/393 Site U1561, South Atlantic Transect

4. Data report: X-ray fluorescence scanning of sediment cores, IODP Expedition 390/393 Site U1559, South Atlantic Transect

5. Expedition 390/393 methods

6. Site U1560

7. Site U1556

8. Expedition 390/393 summary

13. Cardiac involvement in creatine deficiency syndrome

19. Investigation of Benthic Foraminiferal Non-Traditional Stable Isotopes to Reconstruct Methane Fluxes in Sedimentary Environments

20. P-199 Baseline neutrophil to lymphocyte ratio predicts survival in patients with metastatic colorectal cancer treated with cetuximab plus avelumab (CAVE) as a rechallenge strategy

22. Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group

26. 397O Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study

27. 461P Real-time PCR-based assessment of RAS/BRAF mutations in the plasma of metastatic colorectal cancer (mCRC) patients: A single institution experience

28. P-200 Bone metastases from colorectal cancer correlate with biological characteristics of primary tumors: A retrospective analysis from a single institution

29. P-190 A retrospective study of regorafenib versus trifluridine/tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: Multi-institution real-life clinical data

32. Dual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer

33. GLPG 1790, a new selective EPHA2 inhibitor, is active in colorectal cancer cell lines belonging to the CMS4/mesenchymal-like subtype

34. Synergistic activity between niraparib and chemotherapy in colorectal cancer: Molecular determinants from a preclinical model

37. Clinical practice use of liquid biopsy to identify RAS/BRAF mutational status in patients with metastatic colorectal cancer: A single institution experience

38. Optimizing treatment with anti-epidermal growth factor receptor drugs for patients with metastatic colorectal cancer: novel mechanisms of resistance beyond RAS

39. Retrospective study of Regorafenib versus Trifluridine/Tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: a single Italian institution real-life clinical data

40. AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)

41. Functional inhibition of TGF-β in colorectal cancer cells and its interaction with AXL receptor

42. Combination treatment with the PARP inhibitor niraparib and chemotherapeutics in a preclinical model of KRAS/BRAF mutated colorectal cancer cell lines across the four consensus molecular subtypes

43. Receptor tyrosine kinase dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated colorectal cancer cell lines

45. D12 DNA damage signatures in peripheral lymphocytes as biomarkers in prodromal huntington disease

48. 668TiP - Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) colon

Catalog

Books, media, physical & digital resources